32,167 results match your criteria Lymphoma Diffuse Large Cell


Prognostic impact of mutation, proliferative index and cell origin in diffuse large B cell lymphoma.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):50-56. Epub 2018 Oct 24.

Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.

Background: Diffuse large B-cell lymphoma, among non-Hodgkin lymphomas, is one of the most frequent subtypes. Clinical laboratory data and post-treatment outcomes are scarce in the Brazilian population.

Objective: The main objective of this retrospective study was to assess the impact of tumor markers, including the Myeloid differentiation primary response 88 (MYD88) mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.05.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371411PMC
October 2018

CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.

Case Rep Dermatol Med 2019 16;2019:3730915. Epub 2019 Jan 16.

Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

Most primary cutaneous B-cell lymphomas (PCBCL) are CD5 negative, and only a few cases were found to express CD5. We report the first well-documented CD5+ primary cutaneous diffuse large B-cell lymphoma-leg type (PCDLBCL-LT). A 71-year-old woman with a history of Multiple Sclerosis was admitted because of a nodule at the left thigh. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/3730915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354159PMC
January 2019

Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.

Cancer Med 2019 Feb 20. Epub 2019 Feb 20.

Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma. High total metabolic tumor volume (TMTV) calculated using F-FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL. However, high cost and poor access to the imaging facilities hamper wider use of F-FDG PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1973DOI Listing
February 2019

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.

Cell Oncol (Dordr) 2019 Feb 21. Epub 2019 Feb 21.

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.

Purpose: Increased glycolytic activity with accumulation of extracellular lactate is regarded as a hallmark of cancer. In lymphomas, FDG-PET has undeniable diagnostic and prognostic value, corroborating that these tumours are avid for glucose. However, the role of glycolytic metabolism-related molecules in lymphoma is not well known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-019-00426-2DOI Listing
February 2019

Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Aesthet Surg J 2019 Feb 21. Epub 2019 Feb 21.

Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.

Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon type of non-Hodgkin lymphoma occurring in the fluid or capsule adjacent to textured breast implants. Diagnosis of BIA-ALCL of symptomatic patients requires demonstration of large anaplastic cells with uniform expression of CD30 protein on immunohistochemistry.

Objective: The authors investigated a novel, rapid, office-based, and economic in-situ enzyme-linked immunosorbent assay (ELISA) for screening BIA-ALCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjy327DOI Listing
February 2019

Immunochemotherapy for Richter syndrome: current insights.

Immunotargets Ther 2019 5;8:1-14. Epub 2019 Feb 5.

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland,

Richter syndrome (RS) is recognized as the development of a secondary and aggressive lymphoma during the clinical course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most of such histological transformations are from RS to diffuse large B-cell lymphoma (DLBCL-RS, 90%) and Hodgkin's lymphoma (HL-RS, 10%). Histopathological examination is a prerequisite for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S167456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368420PMC
February 2019

Primary Vaginal Non-Hodgkin Lymphoma.

Cureus 2018 Dec 11;10(12):e3713. Epub 2018 Dec 11.

Internal Medicine, Universidad Nacional Mayor De San Marcos, Lima, PER.

Non-Hodgkin lymphoma (NHL) is a type of blood cancer and 25% of NHL patients present with a primary extranodal tumor. Primary NHL of the vagina is extremely rare with only a few cases reported. We present the case of a 79-year-old, grand multipara, Peruvian woman with an eleven-month history of symptoms of pelvic and vaginal pain and vaginal bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3713DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373882PMC
December 2018

Lymphoma diagnostics: getting more from less.

Br J Haematol 2019 Feb 19. Epub 2019 Feb 19.

Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.

In the modern era, clinicians and pathologists increasingly make challenging diagnoses in patients with suspected lymphoma using minimal amounts of diagnostic material. The increase in utilization of minimally invasive procedures, such as fine needle aspiration or needle core biopsies, lead to challenges in our ability to make accurate histopathological assessments of disease, including the integration of new diagnostic and prognostic testing, with smaller amounts of material. The trend towards minimally invasive diagnostics is also often in conflicting interest with researchers seeking to study tissue specimens to better understand the biology and genetics of these diseases to move the field forward. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15788DOI Listing
February 2019

Viral, immunologic, and clinical features of primary effusion lymphoma.

Blood 2019 Feb 19. Epub 2019 Feb 19.

HIV & AIDS Malignancy Branch, Center for Cancer Research (CCR), NCI, Bethesda, MD, United States;

Primary effusion lymphoma (PEL) is an aggressive HIV-associated lymphoma with a relatively poor prognosis in the era of effective HIV therapy. Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent, and approximately 80% of tumors are Epstein Barr virus (EBV) co-infected. A better understanding of how KSHV-related immune dysregulation contributes to the natural history of PEL will improve outcomes. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2019-01
Publisher Site
http://dx.doi.org/10.1182/blood-2019-01-893339DOI Listing
February 2019
1 Read

Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-centre experience.

Q J Nucl Med Mol Imaging 2019 Feb 14. Epub 2019 Feb 14.

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Background: International guidelines support performing baseline positron emission tomography (PET) in lymphoma. Metabolic tumor volume (MTV) measurement has been proposed as a good measurement of disease burden. We investigated if MTV at baseline PET can be predictive of complete response (CR) to first line standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) and in follicular lymphoma (FL) grade 3b. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S1824-4785.19.03130-3DOI Listing
February 2019

CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant.

J Cutan Pathol 2019 Feb 18. Epub 2019 Feb 18.

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.

Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60-81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13446DOI Listing
February 2019

Correlations of mouse lymphoma xenografts with the expressions of MMP-9 and Bcl-2.

Eur Rev Med Pharmacol Sci 2019 Feb;23(3):1176-1183

Department of Hematology, Qingdao Center Hospital, Qingdao, Shandong, P.R. China.

Objective: To establish a mouse lymphoma xenograft model so as to investigate the correlation between the expression of matrix metallopeptidase-9 (MMP-9) and that of B-cell lymphoma 2 (Bcl-2) in lymphomas.

Materials And Methods: Diffuse large Bcl (DLBCL) cells were cultured, and a mouse lymphoma xenograft model was established via the subcutaneous injection. Mouse lymphoma tissues were extracted, and the expressions of MMP-9 and Bcl-2 messenger ribonucleic acids (mRNAs) in the xenograft tumor were detected using Real-time polymerase chain reaction (PCR). Read More

View Article

Download full-text PDF

Source
http://www.europeanreview.org/article/17010
Publisher Site
http://dx.doi.org/10.26355/eurrev_201902_17010DOI Listing
February 2019
1 Read

Phosphoproteomic Analysis of Signaling Pathways in Lymphomas.

Methods Mol Biol 2019 ;1956:371-381

Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Frankfurt, Germany.

Cell fate decisions are controlled by complex signal transduction processes that transmit information via posttranslational protein modifications such as phosphorylation. In lymphoma, as in other cancer types, these signaling networks are often dysregulated and thus contribute to malignant transformation and tumor maintenance. For example, B-cell antigen receptor signals are rewired in certain lymphoma types, such as diffuse large B-cell lymphomas, to promote cell growth and survival of the malignant cell clones. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-9151-8_19
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-9151-8_19DOI Listing
January 2019
1 Read

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.

J Exp Clin Cancer Res 2019 Feb 18;38(1):86. Epub 2019 Feb 18.

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of lymphoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, People's Republic of China.

Background: Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of patients not being cured. BCR-associated kinases (SYK, BTK, and PI3K) inhibitors have exhibited encouraging pre-clinical and clinical effects, as reported by many researchers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1076-4DOI Listing
February 2019

[One case of diffuse large B cell lymphoma primarily presenting in sphenoid sinus].

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2019 Feb;54(2):139-140

Department of Radiology, Henan university huaihe hospital, Kaifeng 475000, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.1673-0860.2019.02.008DOI Listing
February 2019

Intravascular large B-cell lymphoma: The Great Imitator.

Autops Case Rep 2018 Oct-Dec;8(4):e2018055. Epub 2018 Nov 30.

University of Vermont Medical Center, Department of Pathology and Laboratory Medicine. Burlington, Vermont, USA.

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma with an estimated incidence of less than one per million. Unlike other hematopoietic malignancies, lymphadenopathy and hepatosplenomegaly are uncommon, and patients typically present with nonspecific symptoms. IVLBCL presents a diagnostic challenge and patients are usually diagnosed late in the disease course, if at all, and the prognosis is poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4322/acr.2018.055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360824PMC
November 2018

Adrenal Collision Tumor Composed of Pheochromocytoma and Diffuse Large B-Cell Lymphoma: A Case Report.

Int J Hematol Oncol Stem Cell Res 2018 Oct;12(4):249-252

Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Adrenal involvement in the course of malignant lymphoma occurs in about 4% of patients, but primary adrenal lymphoma (PAL) is extremely rare. To the best of our knowledge, only one case study reported the combination of PAL with pheochromocytoma. In the current study, we present the second case who was a 63-year-old man admitted to our hospital with hematuria and abdominal discomfort. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375380PMC
October 2018

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients.

Oncotarget 2019 Jan 22;10(7):717-731. Epub 2019 Jan 22.

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.

Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understood, but effect of rituximab are enhanced by antagonizing cell surface receptor CXCR4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366826PMC
January 2019

[A retrospective analysis of 12 cases of primary thyroid lymphoma].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Feb;51(1):165-170

Department of Endocrinology, Peking University First Hospital, Beijing 100034, China.

Objective: To discuss the clinical characteristics and diagnostic and therapeutic considerations of primary thyroid lymphoma (PTL) by reviewing PTL cases.

Methods: In the study, 12 cases of PTL diagnosed and treated in Peking University First Hospital between January 1995 and September 2015 were identified. The clinical characteristics, management experiences and prognosis of these cases were reviewed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19723/j.issn.1671-167X.2019.01.028DOI Listing
February 2019

[Clinicopathological features and possible prognostic factors in parotid lymphomas].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Feb;51(1):35-42

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.

Objective: To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin.

Methods: Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19723/j.issn.1671-167X.2019.01.007DOI Listing
February 2019

PD-L1 and tumor-associated macrophages in de novo DLBCL.

Blood Adv 2019 Feb;3(4):531-540

Oncology Biomarker Development.

Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death-1 (PD-1), are important negative regulators of immune cell activation. Therapeutically targeting PD-1/PD-L1 in diffuse large B-cell lymphoma (DLBCL) patients with a single agent has limited activity, meriting a deeper understanding of this complex biology and of available PD-L1 clinical assays. In this study, we leveraged 2 large de novo DLBCL phase 3 trials (GOYA and MAIN) to better understand the biologic and clinical relevance of PD-L1 in de novo DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018020602DOI Listing
February 2019
1 Read

The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

PET-CT Center, the First Affiliated Hospital, Zhejiang University. Electronic address:

Background: CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.008DOI Listing
February 2019
1 Read

Driver Network as a Biomarker: Systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.

Bioinformatics 2019 Feb 15. Epub 2019 Feb 15.

Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute; Weill Cornell Medicine of Cornell University, Houston, TX, USA.

Motivation: Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify driver signaling pathways and predict synergistic drug combinations by integrating the knowledge embedded in vast amounts of available pharmacogenomics and omics data.

Results: This tool generates driver signaling networks by processing DNA sequencing, gene copy number, DNA methylation, and RNA-seq data from individual cancer patients using an integrated pipeline of algorithms, including bootstrap aggregating-based Markov random field, weighted co-expression network analysis, and supervised regulatory network learning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btz109DOI Listing
February 2019
6 Reads
4.981 Impact Factor

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India.

South Asian J Cancer 2019 Jan-Mar;8(1):57-59

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.

Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological, clinicopathological characteristics, and treatment outcome of primary GIT diffuse large B-cell lymphoma (PGIL).

Materials And Methods: Newly diagnosed patients of PGIL with DLBCL histology were eligible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_52_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348773PMC
February 2019
1 Read

Primary Esophageal Diffuse Large B-Cell Lymphoma: A Comparative Review of 15 Cases.

J Investig Med High Impact Case Rep 2018 Jan-Dec;6:2324709618820887

5 Abington - Jefferson Health, Abington, PA, USA.

Primary esophageal diffuse large B-cell lymphoma (DLBCL) is an extremely rare clinicopathologic entity. We report one case from our clinical experience and undertake a review of the previously published cases. A systematic literature search of the medical databases PubMed and Google Scholar was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709618820887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305950PMC
February 2019
2 Reads

Head trauma complicated with primary cranial vault lymphoma: A case report.

Medicine (Baltimore) 2019 Feb;98(7):e14465

Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian.

Rationale: Primary cranial vault lymphoma (PCVL) is an extremely rare extranodal lymphoma in the skull. This case study investigates the clinical features, so as to improve the understanding of the diagnosis and therapy.

Patient Concerns: A 31-year-old male presented painful scalp mass at the site of 1-month-old head trauma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014465DOI Listing
February 2019
1 Read
5.723 Impact Factor

Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.

Future Oncol 2019 Feb 13. Epub 2019 Feb 13.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA 02139, USA.

Aim: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL).

Patients & Methods: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated.

Results: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0788DOI Listing
February 2019
1 Read

Primary Hepatic Diffuse Large B-cell Lymphoma Mimicking Acute Fulminant Hepatitis: A Case Report and Review of the Literature.

Eur J Case Rep Intern Med 2018 26;5(6):000878. Epub 2018 Jun 26.

Department of Internal Medicine, Middle East Institute of Health, Faculty of Medical Science, Lebanese University, Hadath, Lebanon.

Primary hepatic lymphoma (PHL) is a rare variant of non-Hodgkin's lymphoma. Diffuse hepatic involvement is uncommon and therefore presentation as progressive hepatitis or acute fulminant hepatic failure is rare. Acute onset of signs and symptoms can mimic a variety of infectious and inflammatory disorders, thus delaying the diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000878DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346882PMC
June 2018
1 Read

Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.

Cureus 2018 Nov 30;10(11):e3660. Epub 2018 Nov 30.

Neurosurgery, Stanford University School of Medicine, Stanford, USA.

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia that affects older adults in the Western world. Symptomatic nervous system invasion in undiagnosed CLL is rare, poorly understood, challenging to treat, and associated with decreased survival. The average survival of CLL patients with central nervous system (CNS) involvement is 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364951PMC
November 2018
1 Read

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.

J Clin Pathol 2019 Feb 12. Epub 2019 Feb 12.

Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Aims: Oxidative stress markers and antioxidant enzymes have previously been shown to have prognostic value and associate with adverse outcome in patients with diffuse large B cell lymphoma (DLBCL). Nuclear factor erythroid 2-related factor 1 (Nrf1) and factor 2 (Nrf2) are among the principal inducers of antioxidant enzyme production. Kelch ECH associating protein 1 (Keap1) is a negative regulator of Nrf2, and BTB (BR-C, ttk and bab) domain and CNC homolog 1 (Bach1) represses the function of both factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2018-205584DOI Listing
February 2019
1 Read

Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.

J Exp Clin Cancer Res 2019 Feb 12;38(1):73. Epub 2019 Feb 12.

Department of Blood Transfusion, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Panfu Rd No.1, Yuexiu District, Guangzhou, 510180, Guangdong, China.

Background: The drug-resistance and relapse of diffuse large B-cell lymphoma (DLBCL), which are related to mesenchymal stem cells (MSCs), have become increasingly common. However, the underlying mechanisms remain elusive.

Methods: CCK 8 assay, colony formation assay, and xenograft mouse model were used to investigate the effects of hBMSCs on DLBCL growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1081-7DOI Listing
February 2019
1 Read

Body size and obesity during adulthood, and risk of lympho-hematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.

Ann Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Epidemiology and Biostatistics, Imperial College, London, United Kingdom.

Background: To summarise the evidence on the associations between body mass index (BMI) and BMI in early adulthood, height, waist circumference (WC) and waist to hip ratio (WHR), and risk of lympho-hematopoietic cancers.

Method: We conducted a meta-analysis of prospective studies and identified relevant studies published up to December 2017 by searching PubMed. A random effects model was used to calculate dose-response summary relative risks (RRs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz045DOI Listing
February 2019
1 Read

Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2019 Feb 12:JCO1801385. Epub 2019 Feb 12.

Jing Wang, MM; Rui Dong, PhD, MD; and Kai Li, PhD, Children's Hospital of Fudan University, Shanghai, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01385DOI Listing
February 2019
1 Read

[Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals].

Nihon Shokakibyo Gakkai Zasshi 2019 ;116(2):177-183

Department of Anatomic Pathology, Kurashiki Central Hospital.

A Japanese male in his 70s with chronic hepatitis C was diagnosed with diffuse large B-cell lymphoma and achieved and maintained complete remission following treatment with eight cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisolone). Seven years later, he received the direct-acting antivirals (DAAs) sofosbuvir/ledipasvir for hepatitis C virus (HCV) genotype 1b. Although the patient achieved sustained virological response immediately after the initial treatment period, laboratory data showed elevation of LD and soluble IL-2R. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/nisshoshi/116/2/116_177
Publisher Site
http://dx.doi.org/10.11405/nisshoshi.116.177DOI Listing
January 2019
3 Reads

Immune profiling and quantitative analysis decipher the clinical role of immune checkpoint expression in the tumor immune microenvironment of DLBCL.

Cancer Immunol Res 2019 Feb 11. Epub 2019 Feb 11.

Hematopathology, The University of Texas MD Anderson Cancer Center

PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for twelve types of cancer and are being studied in diffuse large B-cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma. However, whether both PD-1 and CTLA-4 checkpoints are active and clinically significant in DLBCL is unknown. Whether PD-1 ligands expressed by tumor cells or by the microenvironment of DLBCL are critical for immune checkpoint is unclear. Read More

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0439DOI Listing
February 2019
3 Reads

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center.

Hematol Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Hematology, Internal Medicine Division, Dr. José E. González University Hospital of the School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2579DOI Listing
February 2019
1 Read

Primary neurolymphomatosis of the trigeminal nerve.

Br J Neurosurg 2019 Feb 11:1-4. Epub 2019 Feb 11.

a Department of Neurosurgery , Asahikawa Medical University , Hokkaido , Japan.

We report a case of a primary malignant lymphoma of the trigeminal nerve that was associated with facial pain. A 65-year-old man was examined at another hospital for unilateral facial pain. Carbamazepine was prescribed, but his symptoms did not improve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688697.2019.1568391DOI Listing
February 2019
1 Read

The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.

Cancer Med 2019 Feb 10. Epub 2019 Feb 10.

Department of Haematology, Jagiellonian University, Krakow, Poland.

The prognosis of diffuse large B-cell lymphoma (DLBCL) patients depends on lymphoma- and patient-related risk factors and is best estimated by the international prognostic index (IPI). The aim of the study was to determine whether the average relative dose intensity (ARDI) of an anthracycline-containing regimen could predict DLBCL outcome independently from the IPI. We analyzed 223 white Caucasian DLBCL patients who completed at least four cycles of first-line immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2008DOI Listing
February 2019
1 Read

LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.

Biochem Biophys Res Commun 2019 Mar 7;510(4):594-600. Epub 2019 Feb 7.

Department of Hematology, The Affiliated Hospital of Qingdao University, No.16, Jiangsu Road, Qingdao, Shandong, 266003, China. Electronic address:

Diffuse large B-cell lymphoma (DLBCL) contributes to the cancer-related mortality. Increasing evidence have reported the crucial role of long non-coding RNAs (lncRNAs) in tumorigenesis. Microarray analysis was used to screen out the differentially expressed lncRNAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.01.105DOI Listing
March 2019
1 Read

Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.

Pathol Oncol Res 2019 Feb 9. Epub 2019 Feb 9.

Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, Birmingham, B15 2TT, UK.

SLIT2 has been classified as a major tumour suppressor gene due to its frequent inactivation in different cancer types. However, alterations of SLIT2 expression and relation to patient outcomes in diffuse large B cell lymphoma (DLBCL) remain undefined. The aim of this study was to investigate the expression and the methylation status of SLIT2 gene as well as its relation to patient outcomes in DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00600-9DOI Listing
February 2019
2 Reads

Extranodal diffuse large B cell lymphoma of maxillary sinus presenting as a palatal ulcer.

BMJ Case Rep 2019 Feb 9;12(2). Epub 2019 Feb 9.

Department of Oral Surgery, Amrita School of Dentistry, AIMS Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.

A multitude of disease processes ranging from periodontitis to malignancies can lead to formation of solitary ulcer on the palate. Hence solitary ulcers of palate can often be a challenging one to diagnose. We report an interesting case of a diffuse large B cell lymphoma of the maxillary sinus which perforated the palatal bone and presented clinically as a palatal ulcer. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22860
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-228605DOI Listing
February 2019
3 Reads

[Research Progress of C-Myc in Chronic Myelogenous Leukemia --Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):297-300

Department of Hematology, The First People's Hospital of Huaian Affiliated to Nanjing Medical University, Huaian, 223300, Jiangsu Province, China.E-mail:

As a potential target for cancer treatment, the C-Myc high expresses abnormally in a variety of solid tumors and hematological malignancies in humans. In hematologic malignancies, the increasing expression of C-Myc is associated with poor prognosis of patients diffuse large B-cell lymphoma. However, some studies have shown that high expression of C-Myc might be one of the mechanisms of disease progression and abrupt change, therefore, it can promote the transformation of chronic myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.049DOI Listing
February 2019
1 Read

[Clinicopathological Observation of Primary Renal Non-Hodgkin's Lymphoma--A Report of Two Cases].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):86-90

Department of Pathology, The Changzhou Municipal Second People's Hospital, Affiliated to Nanjing Medical University, Changzhou 213000, Jiangsu Province, China.

Objective: To investigate the clinicopathological and immunohistochemical features as well as diagnosis, differential diagnosis,treatment and prognosis of patients with primary renal non-hodgkin's lymphoma (PRNHL).

Methods: Clinical data of 2 patients with PRNHL from January 2013 to October 2017 were retrospectively analyzed.

Results: One of the two male patients PRNHL aged 51 years old, admitted to hospital for swelling and pain in the right waist, B-ultra sonic examination showed a very solid upper right renal space occupying lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.014DOI Listing
February 2019
2 Reads

[Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):74-79

Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.E-mail:

Objective: To investigate the prognostic evaluation value of fluorodeoxyglucose (FDG) interim positron emission tomography/computed tomography (PET/CT) for diffuse large B cell lymphoma (DLBCL).

Methods: Two hundred and twenty-seven patients with pathologically diagnosed DLBCL underwent 18F-FDG scans at baseline and before 3 cycles of a rituximab-containing chemotherapy regimen. The Visual Deauville score (DS) and changes in maximum standard uptake values (ΔSUVmax) were calculated for tracer for the predominant lesion of each patient, for prediction of progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier method and COX regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.012DOI Listing
February 2019
1 Read

[Clinical Significance of TF and VEGF Expressions on Peripheral CD14 Positive Monocytes in Patients with Diffuse Large B Cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):67-73

Department of Hematology, The Second People's Hospital of Lianyungang, Lianyungang 222006, Jiangsu Province, China.E-mail:

Objective: To investigate the clinical significance of tissue factor (TF) and vascular endothelial growth factor (VEGF) expression on peripheral blood CD14 positive monocytes in patients with diffuse large B cell lymphoma (DLBCL).

Methods: The expressions of TF and VEGF on peripheral CD14 monocytes in 41 patients with DLBCL (DLBCL group) before chemotherapy and after 4 chemotherapeutic courses, and in 20 healthy subjects (control group) were detected by flow cytometry respectively, meanwhile, the relationship of the expression of TF and VEGF with international prognostic indexes (IPI) and short-term effects were analysed.

Results: The expression levels of TF and VEGF on peripheral CD14 monocytes in DLBCL group were significantly higher than those in control group (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.011DOI Listing
February 2019
6 Reads

[Survival Analysis of 148 Patients with Primary Diffuse Large B Cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):61-66

Department of Hematology/Oncology,The First Hospital of Tsinghua University,Beijing 100016,China.E-mail:

Objective: To investigate the clinical outcome of the patients with primary diffuse large B-cell lymphoma(DLBCL).

Methods: Clinical data of 148 patients with DLBCL in our hospital and cancer hospital from March 2006 to April 2016 were retrospectively analyzed. Kaplan-Meier analysis was used to estimate progression-free survival(PFS)and overall survival(OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.010DOI Listing
February 2019
1 Read

[Comparison of Different Staging Systems and Prognostic Analysis in 68 Cases of Primary Intestinal Diffuse Large B Cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):52-60

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy in Tianjin, Tianjin's Clinical Research Center for Cancer,Tianjin 300060, China.E-mail:

Objective: To compare the prognostic value of different staging systems in primary intestinal diffuse large B cell lymphoma(PI-DLPCL), and their correlation with clinicopathological characteristics,treatment and prognosis of PI-DLBCL.

Methods: A total of 68 patients with PI-DLBCL were recruited from January 2009 to July 2017. All the patients underwent staging by using TNM, Lugano, Blackledge and Musshoff system, survival curves for the PI-DLBCL patients were plotted using the Kaplan-Meier method and were judged by the log-rank test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.009DOI Listing
February 2019
2 Reads

An unusual cause of colic stenosis in a renal transplant recipient: primary colonic diffuse large B-cell lymphoma.

Ann Ital Chir 2019 Jan 31;8. Epub 2019 Jan 31.

Background: Primary colic lymphoma represents a rare disease accounting for the 0.2%-0.6% of all large-bowel malignancies. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read
0.683 Impact Factor

Primary pulmonary lymphoma in children.

Orphanet J Rare Dis 2019 Feb 8;14(1):35. Epub 2019 Feb 8.

Department of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, Nanlishi Road 56, Xicheng District, Beijing, China.

Background: Primary pulmonary lymphoma (PPL) is a rare disease, especially in children. We analyse the clinical features of PPL in 4 children to strengthen a understanding of it.

Results: We reported a case series of 4 pediatric patients with PPLs including three diffuse large B-cell lymphomas and one natural killer-T cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-019-1009-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368794PMC
February 2019
1 Read